avelumab,Cabozantinib
Merck,Pfizer
['cabo ', 'ca,022,i', 'avelumab', 'main-cav', 'muc ,(-much)']
main-cav: ph iii rct of avleumab + cabo vs avelumab in la/muc pts primary outcome: os secondary outcomes: pfs, safety/aes, qol measures
enrolment start: mar 2022
estimated completion: dec 2024 #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧